title: Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.
abstract: BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Zachary A
authors.initials: ZA
authors.lastname: Cooper
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Reuben
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Jacob
authors.initials: J
authors.lastname: Austin-Breneman
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. jwargo@mdanderson.org.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Wargo
mesh_terms: D060890:B7-H1 Antigen / Q000378:metabolism*; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D060890:B7-H1 Antigen; D047428:Protein Kinase Inhibitors